ID: ALA3245408

Max Phase: Preclinical

Molecular Formula: C18H23N3O2

Molecular Weight: 313.40

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  N=C(N)c1cccc(OCCCCCOc2ccc(N)cc2)c1

Standard InChI:  InChI=1S/C18H23N3O2/c19-15-7-9-16(10-8-15)22-11-2-1-3-12-23-17-6-4-5-14(13-17)18(20)21/h4-10,13H,1-3,11-12,19H2,(H3,20,21)

Standard InChI Key:  KNSKWZRGTBIMMP-UHFFFAOYSA-N

Associated Targets(non-human)

Acrosin 53 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 313.40Molecular Weight (Monoisotopic): 313.1790AlogP: 3.18#Rotatable Bonds: 9
Polar Surface Area: 94.35Molecular Species: BASEHBA: 4HBD: 3
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 11.16CX LogP: 2.57CX LogD: 0.17
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.29Np Likeness Score: -0.45

References

1. Parrish RF, Straus JW, Paulson JD, Polakoski KL, Tidwell RR, Geratz JD, Stevens FM..  (1978)  Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.,  21  (11): [PMID:722718] [10.1021/jm00209a008]

Source